# INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

> **NCT02977780** · PHASE2 · RECRUITING · sponsor: **Patrick Wen, MD** · enrollment: 460 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Neratinib
- **DRUG:** QBS10072S
- **DRUG:** Abemaciclib
- **DRUG:** CC-115

## Key facts

- **NCT ID:** NCT02977780
- **Lead sponsor:** Patrick Wen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-02-09
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-04-30
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977780, "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02977780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*